159 related articles for article (PubMed ID: 37573477)
1. COVID outcome in pemphigus: Does rituximab make pemphigus patients susceptible to more severe COVID-19?
Aryanian Z; Balighi K; Sajad B; Esmaeli N; Daneshpazhooh M; Mazloumi Tootoonchi N; Beigmohammadi F; Mohseni Afshar Z; Hatami P
J Cosmet Dermatol; 2023 Nov; 22(11):2880-2888. PubMed ID: 37573477
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 Infection in Pemphigus Vulgaris Two Weeks after Rituximab Therapy with Total Recovery: A Case Report.
Róbert L; Kovács A; Sárdy M; Fábián M
Acta Dermatovenerol Croat; 2023 Dec; 31(3):156-157. PubMed ID: 38439728
[TBL] [Abstract][Full Text] [Related]
3. Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: A narrative review.
Beyzaee AM; Rahmatpour Rokni G; Patil A; Goldust M
Dermatol Ther; 2021 Jan; 34(1):e14405. PubMed ID: 33051960
[TBL] [Abstract][Full Text] [Related]
4. Pemphigus vulgaris relapse during the coronavirus disease pandemic.
Saleh MA; Saleh NA
Dermatol Ther; 2022 Apr; 35(4):e15354. PubMed ID: 35108427
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study.
Toosi R; Mahmoudi H; Balighi K; Teimourpour A; Alaeen H; Shaghaghi M; Abedini R; Daneshpazhooh M
J Dermatolog Treat; 2021 Feb; 32(1):33-40. PubMed ID: 31074302
[No Abstract] [Full Text] [Related]
6. Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic?
Uzuncakmak TK; Özkoca D; Askin O; Kutlubay Z
Dermatol Ther; 2021 Jan; 34(1):e14647. PubMed ID: 33296557
[TBL] [Abstract][Full Text] [Related]
7. Rituximab treatment in pemphigus vulgaris: effect on circulating Tregs.
El-Zawahry B; Bassiouny D; Hegazy R; Gawdat H; Shalaby S; Khorshied M; Saleh MA
Arch Dermatol Res; 2017 Sep; 309(7):551-556. PubMed ID: 28631092
[TBL] [Abstract][Full Text] [Related]
8. The use of rituximab as an adjuvant in the treatment of oral pemphigus vulgaris.
Fortuna G; Calabria E; Ruoppo E; Adamo D; Aria M; Amato M; Mignogna MD
J Oral Pathol Med; 2020 Jan; 49(1):91-95. PubMed ID: 31420993
[TBL] [Abstract][Full Text] [Related]
9. A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns.
Tavakolpour S; Aryanian Z; Seirafianpour F; Dodangeh M; Etesami I; Daneshpazhooh M; Balighi K; Mahmoudi H; Goodarzi A
Immunopharmacol Immunotoxicol; 2021 Oct; 43(5):507-518. PubMed ID: 34287098
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of biosimilar rituximab in the treatment of pemphigus vulgaris: a single center experience of 12 cases.
Bardazzi F; Loi C; Vara G; Patrizi A; Di Altobrando A
J Dermatolog Treat; 2022 Feb; 33(1):580-582. PubMed ID: 32068447
[TBL] [Abstract][Full Text] [Related]
11. Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia.
Koszegi B; Stone C; Murrell DF
Front Med (Lausanne); 2023; 10():1149742. PubMed ID: 36999066
[TBL] [Abstract][Full Text] [Related]
12. Rituximab therapy improves recalcitrant Pemphigus vulgaris.
Noormohammadpour P; Ehsani A; Mortazavi H; Daneshpazhooh M; Balighi K; Mofidi M; Gholamali F; Sadeghinia A
EXCLI J; 2015; 14():109-16. PubMed ID: 26417354
[TBL] [Abstract][Full Text] [Related]
13. Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients.
Kim MR; Kim HC; Kim SC
Dermatology; 2011; 223(2):182-8. PubMed ID: 22025028
[TBL] [Abstract][Full Text] [Related]
14. Estimating the susceptibility to SARS-CoV-2 infection with rituximab use for pemphigus vulgaris.
Jafri ZA; Walia S; Ivanic MG; Wu JJ
J Dermatolog Treat; 2022 May; 33(3):1606-1607. PubMed ID: 33375865
[TBL] [Abstract][Full Text] [Related]
15. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review.
Tavakolpour S; Mahmoudi H; Balighi K; Abedini R; Daneshpazhooh M
Int Immunopharmacol; 2018 Jan; 54():131-138. PubMed ID: 29132070
[TBL] [Abstract][Full Text] [Related]
16. Comparison between the efficacy of intralesional rituximab versus intralesional triamcinolone in the treatment refractory Pemphigus Vulgaris lesions: A randomized clinical trial.
Iraji F; Danesh F; Faghihi G; Siadat A; Mokhtari F; Talakoob M; Hafezi H
Int Immunopharmacol; 2019 Aug; 73():94-97. PubMed ID: 31082727
[TBL] [Abstract][Full Text] [Related]
17. Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris.
Werth VP; Joly P; Mimouni D; Maverakis E; Caux F; Lehane P; Gearhart L; Kapre A; Pordeli P; Chen DM;
N Engl J Med; 2021 Jun; 384(24):2295-2305. PubMed ID: 34097368
[TBL] [Abstract][Full Text] [Related]
18. Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): five cases.
Antonucci A; Negosanti M; Tabanelli M; Varotti C
J Dermatolog Treat; 2007; 18(3):178-83. PubMed ID: 17538808
[TBL] [Abstract][Full Text] [Related]
19. Clinical and immunological predictors of post-rituximab paradoxical pemphigus flare: A prospective cohort study.
Gupta V; Ahuja R; Sindhuja T; Imran S; Kumar Viswanathan G; Kumar Tembhre M; Pandey S; Khandpur S
Indian J Dermatol Venereol Leprol; 2024 Mar; ():1-6. PubMed ID: 38595008
[TBL] [Abstract][Full Text] [Related]
20. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris.
El Tal AK; Posner MR; Spigelman Z; Ahmed AR
J Am Acad Dermatol; 2006 Sep; 55(3):449-59. PubMed ID: 16908351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
